A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
A Phase 3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of BNT162b2 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants 12 Through 64 Years of Age Considered at Higher Risk of Severe COVID-19, and Participants ≥65 Years of Age
Sponsor: BioNTech SE
A PHASE3 clinical study on COVID-19 and SARS-COV-2 Infection, this trial is ongoing. The trial is conducted by BioNTech SE and has accumulated 3 data snapshots since 2025. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
3 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jul 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioNTech SE
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .